SNCA has broken out of a descending channel
Catalyst Seneca Biopharma, Inc. (Nasdaq: SNCA) entered into a agreement with a privately held company Leading BioSciences, Inc. (“LBS” for a merger with to form Palisade Bio, Inc.
SNCA has broken out of a descending channel and retested the upper trend line.
The idea is self explanatory targets and stop loss is marked on the chart.
A good risk management is key to success in the financial markets. Risk only a small portion of your portfolio in this risky but potential trade.
Pharmaceuticals
CPRX Catalyst Pharmaceuticals $40M Repurchase P/E Ratio 6.5 WOWCatalyst Pharmaceuticals is a biopharmaceutical company that specializes in therapies for rare neurological and neuromuscular diseases. It announced its fourth-quarter and 2020 financial results on March 15, 2021, reporting a 16% increase in revenue for fiscal 2020 and a 30% increase in operating income. (investopedia.com)
The company posted adjusted earnings of $0.11 per share, up 57% year-over-year, with the figure exceeding analysts’ expectations of $0.09 per share.
The company remains focused on acquiring or in-licensing innovative, technology platforms and early stage programs in therapeutic areas different from neuromuscular diseases. (smarteranalyst.com)
CPRX it`s an easy 50% in my opinion.
$40 Million Share Repurchase.
Market Cap 453.715M.
PE Ratio (TTM) 6.15.
75mil revenue, 119mil earnings in 2020
haven`t seen such a great balance sheet on a penny stock.
now trading at 4,94usd.
3/18/2021 Roth Capital Boost Price Target Buy $6.50 ➝ $7.00
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on the stock with a price target of $9
If you are also interested to test some amazing BUY and SELL INDICATORS that i use, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
AstraZeneca (AZN) Rare Investment Opportunity!AstraZeneca (AZN), W1: Support line + Bollinger bands + Hammer + Sell off
ACAD (ACADIA PHARMACEUTICALS INC) BUY
ACAD LONG SET UP, ACAD Gapped down over 25% to a New 52 week low.
Price should bounce and fill in the Gap in the market
ACAD also filled its previous Buy gap from Sep 4th 2019
Title: Buy ACAD (ACADIA Pharmaceuticals)
Asset: Stock
Platform: Robinhood/WeBull/Etrade/ 401k account
Symbol: ACAD
Type: Buy Market Execution / Buy Limit
Time Frame: 1D
Entry Price 1: $26.50 ACTIVE
Entry Price 2: $22.50(PENDING)
Stop Loss: $19.50 (70 Pips)
Take Profit 1: $33.00 (70 pips)
Take Profit 2: $38.00 (140 pips)
Take Profit 3: $44.00 (200 pips)
Take Profit 4: $54.00 (300pips)
Status: 🏃🏽♂️Active🏃🏽♂️
Sector: Health Technology
Industry: Biotechnology
ACADIA Pharmaceuticals operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R Brann on July 16, 1993 and is headquartered in San Diego CA
SUNPHARMA Can witness Free unadulterated FallThe stock is weak and more so it has been exposed to the shock of heavy volume price level and now facing rejection at higher level. Let it cross 604.20 level then we can take the trade to ride the profit.
Kempharm $KMPH potentially due to slip much further- SHORT$KMPH has very weak support and could retrace much lower regions in near completion of a head and shoulders formation. All signs are grossly bearish, including many large-scale sell orders having been placed in the last five days. The bigger investors have pulled the rug-- Target new entries much lower on this position if possible.
Best,
BDR
After six-week slide, I am buying MerckMerck is one of my favorite pharmaceutical companies. As far as I can tell, it a genuinely ethical and well-managed company with an above-average ESG rating. Merck has executed pretty consistently, with an average of 2% annual sales growth, 2.5% annual dividend growth, 3% annual earnings growth, and 4% annual free cash flow growth over the past several years.
Merck's valuation is quite attractive for a growing, large-cap company. I estimate its forward P/E at 10, forward P/S at 3.4, and PEG under 5. Merck's dividend yield is a juicy 3.76%, and they should have no problem sustaining that given their free cash flow growth. I estimate that Merck has about 16% upside to its median price multiple of the last four years.
Market sentiment is quite bullish on Merck. The average analyst summary score is a "buy" at 6.4/10. Merck has about 30% upside to its average analyst price target. Open interest from option traders is in highly bullish territory, with a put-call ratio of 0.56.
News lately has been a bit negative for Merck. Today they voluntarily withdrew their drug Keytruda for one of its (many) indications because it didn't meet FDA post-marketing requirements. That's not great, but it won't be devastating to Keytruda revenues. Merck's proposed purchase of Pandion Therapeutics is being investigated for procedural problems, which also isn't great. Plus, the FDA delayed approval of Merck's application for emergency approval for its Covid-19 drug until it produces more data.
On the other hand, Merck just submitted a New Drug Application for gefapixant and cut a billion-dollar commercialization deal for Xevinapant. Both those things are positives for the company. Plus, Merck got some positive attention recently due to a large purchase of its stock by Warren Buffett's investment fund.
In technical terms, Merck obviously has been in a downtrend, but it's approaching trend line support. I'm looking at buy tomorrow in the $71.50-71.75 range if Merck continues to dip toward support.
OCUGEN Inc. Very interesting chart to follow.***Do your own research, this is just for educational purpose. Not an investment advice.
MRK - Merck & Co - WEEKLY Setup - Holding the 200emaI Hate Trading Pharma But...
MRK
BUYZONE = 74 - 76
Cost Avg Down (CAD) = 72 - 70
1st Target = 79
2nd Target = 82
3rd Target = 86
HODL Target = ATH
______________________________________________________________________________________________________________________
This content is for informational, educational and entertainment purposes only. This is not in any way, shape or form financial or trading advice.
Good luck, happy trading and stay chill,
2degreez
Vistagen (VTGN): My opinion NASDAQ:VTGN This isn't financial advice (hell no). I like this stock. The company has potential. This is a nice buying opportunity in non-expert opinion. So, I'm scooping up before their phase 3 trials.
ALNA ALNA has come to test the descending trendline that has lasted for 3 years, the accumulation phase was very long and now it seems on the way to reverse the trend, a reversal confirmed by the crossing of the 20 and 50 weekly moving averages
GERN GERN, waiting for the breakkout I highlight this lateral phase that has lasted for several months, within what seems to me a triangle in which the title has already passed the half of the figure
Tonix Pharmaceuticals LONGTERM FORECAST Weekly chart outlook for the long term. I see some upside in the near future . Lets see how this plays out. Mainly publishing to come back and study the price action.
IMUXIMUX, it seems to me in an accumulation phase, phase trapped in a triangle, the eventual breakdown of the descending train will give us confirmation that the lateral phase is over
CXRXF Long IdeaCXRXF has been consolidating for a long time but now presents a low risk buy in. Notice the two trend lines, we are currently at the lower one. It could drop back 10% but I suspect even if it does, it will eventually drift towards the upper trend line. That's a nice 46% gain from here. Who knows, if it breaks the upper line it could really run.
ALNA ALNA is now an alt test of the static and dynamic resistances that pass in the 1.60-170 area, I do not think it is an easy level to overcome and leave behind, but certainly in an interesting moment to follow
ADMP money $want it to stay above ~1.47 level here for the micro. if it resolves to the bullish over the previous high, then looking for 2 to 3 for short term target
not financial advice
$GILD ELLIOTWAVES$GILD is looking bullish going into 2021
We need a breakout of this downtrend channel for the impulsive waves to be valid, look for a break at the red trendline as well as a retest as support in wave 4
PHARMANIAGASupport 4900.
Long term prospek sebab vaccine player.
Distribute vaccine Sinovac.
Cl below 4000.
Overextended to the downside, Corrective IMPULSE is DUE! (TMBR)Here is a low float pharmaceutical company with a hot bargain of a deal!
We currently sit on a very special only once every couple of years type of moment. MAJOR structural support is being tapped right now from a 7 year decline!
Pharmaceutical and Biotech sector look HOT and READY!
I'm starting to think a 4x move ain't so crazy.
I think it looks like a good long term play.
